Shares of Optimi Health fell 10.1% to $4.64 on June 9, erasing the prior session's gains as investors cashed out of a rally fueled by the company's ibogaine drug-development announcement. The selloff underscores a recurring pattern for this micro-cap psychedelic drugmaker: headline-driven surges followed by swift reversals, leaving shareholders to weigh genuine long-term potential against a still-tiny business with no ibogaine revenue in sight.
A Fresh Catalyst That Lit Up a Thinly Traded Stock. Optimi announced June 8 that it had secured naturally derived ibogaine from two sources, with finished drug product development set to begin this summer at its facility in British Columbia.
The company plans standardized 50 mg and 100 mg capsules for research and regulated access programs. That news pushed shares to $5.16 — but with only roughly 5.6 million shares outstanding and a market cap of approximately $31.7 million , even modest volume swings can produce outsized price moves. Today's reversal to $4.64 puts the stock 26% below its $6.25 IPO price from just three weeks ago.
Real Government Money, But Long Regulatory Runways. The excitement traces back to an April 18 executive order signed by President Trump directing federal agencies to accelerate research, regulatory review, and patient access for psychedelic drug products, including ibogaine.
The order includes a $50 million federal allocation from ARPA-H that could be paired with Texas's own $50 million ibogaine research commitment — real money, but earmarked for clinical trials, not commercial purchases. Critically, ibogaine remains a Schedule I substance in the United States , meaning Optimi cannot sell there without fundamental regulatory change.
A Manufacturing Edge That Still Needs Customers. Canada's regulatory environment and Optimi's existing licenses position the company as a compliant base for ibogaine manufacturing , a genuine advantage since few competitors hold equivalent certifications. Optimi is already commercial-stage in Australia, where physicians prescribe its MDMA for PTSD and psilocybin for treatment-resistant depression. But Australian sales remain small, and the ibogaine product has not generated a single dollar yet.
IPO Investors Already Underwater. The company raised roughly $15 million through an oversubscribed Nasdaq offering at $6.25 per share just three weeks ago. At today's price, every IPO buyer is sitting on a 25.8% loss. That overhang, combined with broader market weakness, makes further profit-taking likely until Optimi delivers concrete milestones — completed manufacturing validation, signed supply agreements, or clinical trial partnerships — that prove the ibogaine opportunity is more than a press release.